Health-related Quality of Life After 12 Months Post Discharge in Patients Hospitalised with COVID-19-related Severe Acute Respiratory Infection (SARI): a Prospective Analysis of SF-36 Data and Correlation with Retrospective Admission Data on Age,...

Overview

Journal BMJ Open

Specialty General Medicine

Date 2024 Mar 20

PMID 38508629

Authors

Gavin Wright

Keerthi Senthil

Amir Zadeh-Kochek

Jonathan Heung-San Au

Jufen Zhang

Jiawei Huang

Ravi Saripalli

Mohiuddin Khan

Omar Ghauri

San Kim

Zakiuddin Mohammed

Carol Alves

Gouri Koduri

Affiliations

Soon will be listed here.

Abstract

Objective: To assess the impact of HRQoL in patients hospitalised with COVID-19-related SARI at 1 year post discharge, focusing on the potential impact of age, frailty, and disease severity.

Method: Routinely collected outcome data on 1207 patients admitted with confirmed COVID-19 related SARI across all three secondary care sites in our NHS trust over 3 months were assessed in this retrospective cohort study. Of those surviving 1 year, we prospectively collected 36-item short form (SF-36) HRQoL questionnaires, comparing three age groups (<49, 49-69, and the over 69-year-olds), the relative impact of frailty (using the Clinical Frailty Score; CFS), and disease severity (using National Early Warning Score; NEWS) on HRQoL domains.

Results: Overall mortality was 46.5% in admitted patients. In our SF-36 cohort (n=169), there was a significant reduction in all HRQoL domains versus normative data; the most significant reductions were in the (p<0.001) across all ages and the (p<0.01) in the 49-69 year age group, with age having no additional impact on HRQoL. However, there was a significant correlation between p versus CFS (the correlation coefficient=-0.37, p<0.05), though not NEWS, with no gender difference observed.

Conclusion: There was a significant reduction in all SF-36 domains at 1 year. Poor CFS at admission was associated with a significant and prolonged impact on physical parameters at 1 year. Age had little impact on the severity of HRQoL, except in the domains of and the overall .

Citing Articles

Analysis of data of COVID lockdown period: Comorbidity and fatality rates in a few districts of Assam, India.

Choudhury A, Sarma K, Dutta L, Misra D, Choudhury A, Sarma R Data Brief. 2024; 57:110974.

PMID: 39429747 PMC: 11490760. DOI: 10.1016/j.dib.2024.110974.

Social Networks as a Key Health Determinant in Acute Illness Recovery: A Lesson from the COVID-19 Pandemic.

Pan D, Diaz J, Weidman K, Graham J, Goyal P, Rajan M Am J Med. 2024; 138(3):541-549.e5.

PMID: 38677397 PMC: 11502506. DOI: 10.1016/j.amjmed.2024.04.024.

References

Davis H, Assaf G, McCorkell L, Wei H, Low R, Reem Y . Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021; 38:101019. PMC: 8280690. DOI: 10.1016/j.eclinm.2021.101019. View

Halpin S, McIvor C, Whyatt G, Adams A, Harvey O, McLean L . Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J Med Virol. 2020; 93(2):1013-1022. DOI: 10.1002/jmv.26368. View

Heesakkers H, van der Hoeven J, Corsten S, Janssen I, Ewalds E, Simons K . Clinical Outcomes Among Patients With 1-Year Survival Following Intensive Care Unit Treatment for COVID-19. JAMA. 2022; 327(6):559-565. PMC: 8787680. DOI: 10.1001/jama.2022.0040. View

OKelly B, Vidal L, Avramovic G, Broughan J, Connolly S, Cotter A . Assessing the impact of COVID-19 at 1-year using the SF-12 questionnaire: Data from the Anticipate longitudinal cohort study. Int J Infect Dis. 2022; 118:236-243. PMC: 8920113. DOI: 10.1016/j.ijid.2022.03.013. View

Wang H, Li X, Yan Z, Sun X, Han J, Zhang B . Potential neurological symptoms of COVID-19. Ther Adv Neurol Disord. 2020; 13:1756286420917830. PMC: 7119227. DOI: 10.1177/1756286420917830. View

Sablerolles R, Lafeber M, van Kempen J, van de Loo B, Boersma E, Rietdijk W . Association between Clinical Frailty Scale score and hospital mortality in adult patients with COVID-19 (COMET): an international, multicentre, retrospective, observational cohort study. Lancet Healthy Longev. 2021; 2(3):e163-e170. PMC: 7906710. DOI: 10.1016/S2666-7568(21)00006-4. View

Liu K, Zhang W, Yang Y, Zhang J, Li Y, Chen Y . Respiratory rehabilitation in elderly patients with COVID-19: A randomized controlled study. Complement Ther Clin Pract. 2020; 39:101166. PMC: 7118596. DOI: 10.1016/j.ctcp.2020.101166. View

Burholt V, Nash P . Short Form 36 (SF-36) Health Survey Questionnaire: normative data for Wales. J Public Health (Oxf). 2011; 33(4):587-603. DOI: 10.1093/pubmed/fdr006. View

Moore S, Wierenga K, Prince D, Gillani B, Mintz L . Disproportionate Impact of the COVID-19 Pandemic on Perceived Social Support, Mental Health and Somatic Symptoms in Sexual and Gender Minority Populations. J Homosex. 2021; 68(4):577-591. DOI: 10.1080/00918369.2020.1868184. View

10.

Rogers J, Chesney E, Oliver D, Pollak T, McGuire P, Fusar-Poli P . Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020; 7(7):611-627. PMC: 7234781. DOI: 10.1016/S2215-0366(20)30203-0. View

11.

Ngai J, Ko F, Ng S, To K, Tong M, Hui D . The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status. Respirology. 2010; 15(3):543-50. PMC: 7192220. DOI: 10.1111/j.1440-1843.2010.01720.x. View

12.

Ware Jr J, Gandek B . Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol. 1998; 51(11):903-12. DOI: 10.1016/s0895-4356(98)00081-x. View

13.

Neville T, Hays R, Tseng C, Gonzalez C, Chen L, Hong A . Survival After Severe COVID-19: Long-Term Outcomes of Patients Admitted to an Intensive Care Unit. J Intensive Care Med. 2022; 37(8):1019-1028. PMC: 8990100. DOI: 10.1177/08850666221092687. View

14.

Ramasamy M, Minassian A, Ewer K, Flaxman A, Folegatti P, Owens D . Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2020; 396(10267):1979-1993. PMC: 7674972. DOI: 10.1016/S0140-6736(20)32466-1. View

15.

Gray W, Navaratnam A, Day J, Wendon J, Briggs T . COVID-19 hospital activity and in-hospital mortality during the first and second waves of the pandemic in England: an observational study. Thorax. 2021; 77(11):1113-1120. DOI: 10.1136/thoraxjnl-2021-218025. View

16.

Logue J, Franko N, McCulloch D, McDonald D, Magedson A, Wolf C . Sequelae in Adults at 6 Months After COVID-19 Infection. JAMA Netw Open. 2021; 4(2):e210830. PMC: 7896197. DOI: 10.1001/jamanetworkopen.2021.0830. View

17.

Mao L, Jin H, Wang M, Hu Y, Chen S, He Q . Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020; 77(6):683-690. PMC: 7149362. DOI: 10.1001/jamaneurol.2020.1127. View

18.

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

19.

Rowen D, Brazier J, Roberts J . Mapping SF-36 onto the EQ-5D index: how reliable is the relationship?. Health Qual Life Outcomes. 2009; 7:27. PMC: 2683169. DOI: 10.1186/1477-7525-7-27. View

20.

Colombo C, Colombo R, Maves R, Branche A, Cohen S, Elie M . Performance Analysis of the National Early Warning Score and Modified Early Warning Score in the Adaptive COVID-19 Treatment Trial Cohort. Crit Care Explor. 2021; 3(7):e0474. PMC: 8280088. DOI: 10.1097/CCE.0000000000000474. View